A Phase II, Open-Label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients With Malignant Melanoma Pre-treated With Recombinant CDX-301, a Recombinant Human Flt3 Ligand

Trial Profile

A Phase II, Open-Label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients With Malignant Melanoma Pre-treated With Recombinant CDX-301, a Recombinant Human Flt3 Ligand

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Sep 2017

At a glance

  • Drugs CDX 1401 (Primary) ; FLT-3 ligand; Poly ICLC
  • Indications Malignant melanoma; Skin tumours
  • Focus Pharmacodynamics
  • Most Recent Events

    • 09 Sep 2017 Results presented at the 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
    • 10 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top